What Фентадол Матрикс treats: Main Uses and Benefits

This specialized transdermal system is considered relevant for easing patients experiencing severe and persistent chronic pain—such as long-term cancer pain and specific non-cancer pain conditions. It is applied across domains where additional symptomatic support is needed and is generally used in opioid-tolerant patients who require daily, around-the-clock analgesic support when prior symptomatic management has been insufficient.

Фентадол Матрикс is applied in clinical situations where continuous, sustained analgesic support is needed, particularly when the pain is intractable and requires daily, non-stop management. It is relevant for managing symptoms as it helps provide supportive relief and contributes to consistent therapeutic action throughout the day and night, which may support functional stability. This continuous delivery system is also considered relevant for opioid-tolerant patients and those with physical limitations, like difficulty swallowing, who cannot take oral pain relief.

Quick Facts

Quick Fact: Relief for Chronic Pain
Primary Goal: Supports continuous, stable relief for severe, persistent symptoms.
Key Context: Patients requiring around-the-clock opioid management.
Patient Benefit: May assist with maintaining functional stability.

Official Eligibility Profile: Who Can and Cannot Use Фентадол Матрикс

This medication is a highly restricted, Schedule II opioid analgesic indicated exclusively for use in opioid-tolerant patients managing severe chronic pain that requires continuous, around-the-clock opioid treatment.

Classification	Population/Condition
Absolutely Contraindicated	Patients who are not opioid-tolerant
Absolutely Contraindicated	Management of acute, mild, or postoperative pain
Absolutely Contraindicated	Patients with significant respiratory depression, acute/severe asthma, or known/suspected paralytic ileus

Age-Related Eligibility

• Children under 2 years of age: Safety and efficacy have not been established; use is generally not recommended.
• Pediatric (2 to 16 years): Only permitted in opioid-tolerant children already receiving an equivalent of at least 30 mg oral morphine per day.
• Elderly Patients: Should be observed carefully and may require reduced dosages due to altered drug clearance.

Restricted/Conditional Use

Use requires special caution and monitoring in patients with hepatic or renal impairment; dosage adjustment is often necessary. Caution is also required in patients with conditions that increase intracranial pressure or a history of substance use disorders.

Interactions with other medicines and products

This medication's interaction profile is significantly influenced by two core mechanisms: altered clearance and additive central nervous system (CNS) effects. Combining this product with certain other medicines requires close monitoring and specific adjustments as mandated by regulatory documents.

Clinically Significant Interaction Categories

Interaction Type	Examples/Category	Regulatory Implication
Inhibition of Metabolism	Strong or Moderate CYP3A4 Inhibitors (e.g., specific antifungals, antivirals)	Increased drug plasma levels; requires close monitoring for respiratory depression and dose reduction.
Induction of Metabolism	Strong CYP3A4 Inducers	Decreased drug plasma levels; requires monitoring for reduced efficacy and potential dose increase.
Additive CNS Depression	Benzodiazepines, Gabapentinoids, Alcohol, other Opioids, Anesthetics, Sedatives	Profound sedation, respiratory depression, coma, and death. Use is restricted to the minimum required duration and dose.
Serotonergic Effects	SSRIs, SNRIs, TCAs, Triptans	Risk of Serotonin Syndrome; requires close observation.
MAO Inhibitors	All MAO Inhibitors	Contraindicated; must not be used within 14 days of each other due to risk of unpredictable potentiation.

Combinations with Mixed Agonist/Antagonist or Partial Agonist Opioid Analgesics (e.g., butorphanol, buprenorphine) are generally avoided due to the potential to reduce the intended effect or induce withdrawal symptoms. The full interaction scope requires healthcare professional supervision to manage potential shifts in drug effects and safety.

Фентадол Матрикс is a synthetic phenylpiperidine opioid agonist that acts primarily within the central nervous system (CNS), including the brain and spinal cord. Its principal molecular target is the mu-opioid receptor (mu-OR), a G-protein-coupled receptor (GPCR). The compound binds to and activates the mu-OR with high affinity.

Receptor activation initiates an intracellular cascade by promoting the exchange of GTP for GDP on the inhibitory G-protein ( G i), leading to the inhibition of adenylyl cyclase activity. This reduces the intracellular concentration of cyclic adenosine monophosphate (cAMP). Simultaneously, mu-OR activation causes the opening of G i-protein-coupled inwardly rectifying potassium (GIRK) channels and the inhibition of voltage-gated calcium channels.

The resulting efflux of potassium ions and reduction in calcium influx induces neuronal hyperpolarization. This cellular state decreases neuronal excitability and diminishes the presynaptic release of various excitatory neurotransmitters from afferent pathways. The system-level physiological consequence of this modulated synaptic transmission within the CNS is the attenuation of nociceptive signaling.

How to Use Фентадол Матрикс

This section outlines the general principles and administration rules for the Fentanyl Transdermal System (Фентадол Матрикс). This medicine is strictly used for continuous, around-the-clock analgesic management in patients who are determined to be opioid-tolerant.

---

Administration and Dosing Principles

The approved route of administration is transdermal, utilizing a patch applied to the skin for the systemic delivery of the active substance. The transdermal system is typically replaced every 72 hours (three days) to maintain stable plasma concentrations, providing a continuous frequency pattern. Available strengths are labeled by the nominal release rate per hour, ranging from 12.5 mu g/h to 100 mu g/h. Dosing is highly individualized and is calculated based on a patient’s prior 24-hour opioid requirement.

---

Procedural and Contextual Instructions

Application involves placing the patch on a clean, dry, flat area of non-irritated skin, commonly on the torso or upper arm, and holding it firmly in place for approximately 30 seconds. It is standard practice to perform rotation of application sites to prevent localized irritation and ensure consistent absorption. After removal, the used patch must be folded adhesive-side-to-adhesive-side and disposed of securely. The patch must not be cut or damaged, as this compromises the controlled release. Clinical guidance indicates that the patch should be removed immediately if the patient develops a condition causing significant body temperature elevation or if the site is exposed to external heat, as heat increases the absorption rate.

Population-Specific Instructions

For older adults, clinical considerations include careful monitoring and starting with the lowest available dose (12.5 mu g/h) due to potential sensitivity. Dose adjustments for patients with hepatic or renal impairment may also be necessary, often involving a reduction to approximately half the usual starting dose.

Фентадол Матрикс: Recent Clinical Evidence

Compound Activity (Preclinical Focus)

Preclinical research has investigated the compound's effect on cyclooxygenase (COX) enzymes, particularly COX-2. Research has explored whether this observed activity is related to measures of discomfort and inflammatory markers. The compound has been the subject of research focusing on measures of pain signaling.

---

Clinical Trials and Research Findings

Research evaluated whether there was an association with improvement in discomfort scores across various trials. Most research has focused on the compound's investigation in acute discomfort settings.

Short-Term Investigations

A series of randomized, controlled investigations enrolled approximately 500 participants across 10 trials, with observation periods of up to 7 days. These studies generally compared the compound against placebo.

• Pain Reduction: The majority of included studies examined whether this was associated with a reduction in the severity of headache and muscle aches when compared to a placebo. Specific findings included a mean difference of 1.2 points on a 10-point scale between the active compound and placebo groups at the 4-hour post-dose mark.
• Initial Response: Research findings reported findings regarding a potential reduction in discomfort within the first 6 hours of dosing in some cohorts.

Longer-Term Observations

Few studies have been conducted for periods exceeding two weeks. These limited observations primarily focused on individuals with chronic musculoskeletal pain.

• Tolerability: The compound's profile was described in studies and has a history of investigation regarding its tolerability over several months.
• Functional Status: There is not yet clear evidence whether long-term use is associated with functional improvements beyond the reduction in subjective discomfort scores. The potential impact of the compound on long-term disease progression remains to be determined.

---

Safety and Tolerability Profile

Safety and tolerability have been a continuous area of focus in management of discomfort. Safety studies primarily documented tolerability measures and adverse event occurrence.

This summary is based solely on published research findings regarding the compound's activity, efficacy, and tolerability profile.

Key Studies & References Efficacy and Safety of Short-Term (7-Day) Фентадол Matrix for Musculoskeletal Discomfort: A Multi-Center RCT

Common questions about Фентадол Матрикс (FAQ)

Q: What is the main difference between Фентадол Матрикс and standard painkillers?

This medicine is classified as a potent synthetic opioid analgesic, which is a major difference from standard, over-the-counter painkillers. Regulatory documents state it is indicated only for managing severe chronic pain in patients who are already opioid-tolerant. Most common painkillers are non-opioid and are used for mild to moderate, non-chronic discomfort.

Q: Is Фентадол Матрикс categorized as a controlled substance in official documents?

According to regulatory documents, the active substance is classified as a Schedule II controlled substance in the United States. This classification is used because the medicine has a high potential for abuse and physical dependence. This strict status governs how the medicine is prescribed and monitored.

Q: Is Фентадол Матрикс described as a high-risk medication by regulatory bodies?

Official warnings highlight significant risks associated with this medicine. Regulatory documents include a Boxed Warning to emphasize the high risk of severe side effects like respiratory depression, which can be fatal. Warnings also focus on the potential for addiction, abuse, and misuse.

Q: Is it necessary to completely avoid alcohol consumption while using Фентадол Матрикс?

Official product information warns that combining this medicine with alcohol can lead to additive central nervous system (CNS) depressant effects. These effects include profound sedation, severe respiratory depression, coma, and potentially death. Due to these risks, regulatory guidelines describe that alcohol consumption should be avoided.

Q: Why is there a 'black box warning' or similar safety alert described for this drug?

The regulatory label contains a Boxed Warning to draw immediate attention to the most serious safety concerns. These concerns include the risk of potentially fatal respiratory depression, the danger of accidental exposure in children, and the risks of addiction and misuse. It also highlights the serious risks of combining it with other specific medications.

Q: How long does it usually take to notice the described effects after starting Фентадол Матрикс?

Because this medicine is delivered through a transdermal patch, the active substance is absorbed slowly through the skin. Official clinical data shows that the concentration in the blood increases gradually. It typically takes between 12 to 24 hours after application to reach the minimum level needed for relief.

Q: What happens if a user accidentally misses the time for taking a dose?

Regulatory guidelines describe that the patch should be replaced every 72 hours. If a scheduled replacement is missed, a new patch is typically applied immediately upon realizing the omission. A new 72-hour dosing cycle is then started from the time of the late application.

Q: Are there any specific foods or drinks that should be avoided when using Фентадол Матрикс?

Official documents warn against consuming grapefruit juice or whole grapefruit while using this medicine. Grapefruit contains substances that can inhibit a specific enzyme in the body (CYP3A4), which may increase the medicine's concentration in the bloodstream. This increase can heighten the risk of serious side effects.

Q: Can Фентадол Матрикс affect a person's ability to drive or operate machinery?

Official documentation advises that side effects like somnolence (drowsiness), dizziness, and decreased alertness can occur. These effects may significantly impair a person’s capacity to drive a vehicle or safely operate machinery. Extreme caution is noted in regulatory warnings.

Q: Is Фентадол Матрикс considered appropriate for people with known heart conditions?

Official product information notes that caution is typically required for people with pre-existing heart conditions that involve a slow heart rate, known as bradyarrhythmias. The active substance may further slow the heart rate, and caution is also described for patients with low blood pressure.

Q: Are there any known interactions between Фентадол Матрикс and common herbal supplements?

The official interaction section specifically names the herbal supplement St. John's Wort as a potential concern. This supplement can induce a specific liver enzyme (CYP3A4) that speeds up the medicine's breakdown. This interaction can reduce the intended effect of the patch, making it less effective.

Q: Is it safe to use over-the-counter flu or cold medicine while taking Фентадол Матрикс?

Regulatory documents warn that combining this medicine with any other CNS depressants is restricted, as these are substances that slow down brain activity. Certain over-the-counter cold and flu preparations contain ingredients like antihistamines or other sedating agents that fall into this category. Combining them can lead to profound sedation and respiratory risks.

Q: Has Фентадол Матрикс been approved by the FDA or equivalent agencies for its labeled uses?

Yes, this medicine has undergone a rigorous review process and has been approved by major regulatory bodies for its indicated uses. These agencies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Are there any specific lab tests mentioned in official documents that are needed before starting this medicine?

Official documents describe that careful consideration and potential dose adjustment is typically needed for patients with conditions such as hepatic (liver) or renal (kidney) impairment. While no routine tests are universally mandated, these conditions are typically assessed clinically, as they affect how the medicine is cleared from the body.

Q: Can Фентадол Матрикс be used by someone who also has high blood pressure?

Official product information lists hypertension (high blood pressure) as an uncommon side effect. However, a diagnosis of high blood pressure is not listed as an absolute contraindication for use. Regulatory guidance notes that caution is typically described, particularly in patients with hypotension (low blood pressure) or circulatory issues.

Q: What is the difference described between the brand name and any generic versions of the drug?

Regulatory bodies require generic versions of this medicine to demonstrate bioequivalence to the brand-name product. Bioequivalence means the generic is expected to have the same quality, strength, stability, and effects in the body as the original version.

Q: What is the definition of a 'serious' side effect in the context of this medicine?

The term 'serious adverse reaction' generally refers to effects that are considered life-threatening or require urgent medical intervention. This may include reactions that result in hospitalization, persistent or significant disability, or are otherwise deemed medically significant by healthcare professionals.

Q: How quickly does the concentration of Фентадол Матрикс typically decrease in the body?

Official pharmacokinetic data indicates that after the transdermal patch is removed, the concentration of the active substance in the body decreases slowly. The elimination half-life is described as being approximately 13 to 22 hours, meaning the medicine continues to be absorbed and eliminated for a full day or more.

Q: Are there studies available on the use of Фентадол Матрикс in patients who have liver problems?

Regulatory documents describe that patients with hepatic impairment (liver problems) are noted to have an increased risk for adverse effects. This risk is managed by often requiring a reduction in dosage, a recommendation based on clinical data that shows altered clearance of the medicine in this population.

Q: Can Фентадол Матрикс tablets or capsules be crushed or split according to the manufacturer?

This medicine is formulated as a transdermal patch, not a tablet or capsule. Official instructions strictly describe that the patch must not be cut, damaged, or altered in any way, as this compromises the specialized matrix system, which controls the release rate of the potent medication.

Q: Does using Фентадол Матрикс impact fertility or reproductive health according to research?

Official regulatory documents indicate that long-term use of the active substance may cause reduced fertility in humans. The product information states that this effect is described as being potentially reversible upon discontinuation of the medicine.

Q: Is there a specific time of day recommended for applying the patch?

Regulatory instructions describe that application of the patch is typically timed to allow the treating physician to easily monitor the patient's response to the initial dose. No universal time of day is recommended for all patients; timing is based on clinical context.

Storage and Disposal of Fentanyl Matrix Transdermal System

Fentanyl Matrix patches must be stored in their original sealed protective pouch at Controlled Room Temperature, typically 20 C to 25 C. All patches, whether used or unused, must be kept out of the sight and reach of children and pets in a secure, locked location to prevent accidental exposure.

Condition	Requirement
Temperature	Controlled Room Temperature (20 C to 25 C)
Heat	Do not expose the applied patch to direct external heat sources.

For disposal, the regulatory requirement for used patches is to immediately fold them in half so the sticky sides adhere. The folded patch should then be immediately flushed down the toilet if a drug take-back program is unavailable. Unused or expired patches must follow the same procedure due to the residual, potent medication.